NASDAQ:PRDS Pardes Biosciences (PRDS) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free PRDS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.16▼$2.1650-Day Range$2.13▼$2.1652-Week Range$0.75▼$3.93Volume400 shsAverage Volume359,530 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pardes Biosciences alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Pardes Biosciences Stock (NASDAQ:PRDS)Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now PRDS Stock News HeadlinesOctober 31, 2023 | yahoo.comPardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo WeatherAugust 31, 2023 | finance.yahoo.comPardes Biosciences Announces Closing of Tender OfferApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.August 28, 2023 | finance.yahoo.comMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesAugust 17, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 3, 2023 | msn.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28July 19, 2023 | marketwatch.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)April 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.July 18, 2023 | msn.comJMP Securities Downgrades Pardes Biosciences (PRDS)July 17, 2023 | benzinga.comPRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to ShareholdersJuly 17, 2023 | msn.comPardes Biosciences stock rallies on buyout offer from MediPacificJuly 17, 2023 | benzinga.comWhy Pardes Biosciences Shares Are Rising MondayJuly 17, 2023 | markets.businessinsider.comPardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-marketJuly 17, 2023 | finance.yahoo.comPardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsJune 5, 2023 | finance.yahoo.comAll You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to BuyMay 17, 2023 | seekingalpha.comPardes Biosciences Seeking Strategic AlternativesMay 9, 2023 | markets.businessinsider.comPardes Biosciences (PRDS) Receives a Hold from SVB SecuritiesMay 6, 2023 | barrons.comPardes Biosciences Inc.May 6, 2023 | finanznachrichten.dePardes Biosciences, Inc: Pardes Biosciences Reports First Quarter 2023 Financial ResultsMay 5, 2023 | msn.comRecap: Pardes Biosciences Q1 EarningsMay 5, 2023 | finance.yahoo.comPardes Biosciences Reports First Quarter 2023 Financial ResultsApril 12, 2023 | benzinga.comAnalyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?April 7, 2023 | seekingalpha.comPardes Biosciences cut at Jefferies on COVID drug failureApril 4, 2023 | msn.comSVB Leerink Downgrades FS Development Corp II (PRDS)April 4, 2023 | markets.businessinsider.comSVB Securities downgrades Pardes Biosciences (PRDS) to a HoldApril 3, 2023 | msn.comPardes slumps ~10% after COVID drug trial failure prompts strategic reviewSee More Headlines Receive PRDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PRDS CUSIPN/A CIK1822711 Webwww.pardesbio.com Phone415-649-8758FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.36% Return on Assets-40.71% Debt Debt-to-Equity RatioN/A Current Ratio81.72 Quick Ratio81.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.86Miscellaneous Outstanding Shares62,012,000Free Float36,711,000Market Cap$133.95 million OptionableNot Optionable Beta0.42 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Thomas G. Wiggans (Age 71)CEO & Chairman Comp: $859.4kDr. Uri A. Lopatin M.D. (Age 51)Founder & Director Comp: $786.96kMs. Heidi Henson CPA (Age 57)Chief Financial Officer Comp: $564.6kMs. Elizabeth Haber Lacy J.D. (Age 56)Gen. Counsel & Corp. Sec. Key CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEAccretion AcquisitionNASDAQ:ENERHome Plate AcquisitionNASDAQ:HPLTGlobal Technology Acquisition Corp. INASDAQ:GTACView All Competitors PRDS Stock Analysis - Frequently Asked Questions Should I buy or sell Pardes Biosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares. View PRDS analyst ratings or view top-rated stocks. This page (NASDAQ:PRDS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
